

Quality Affordable Healthcare Products™

Perrigo Fiscal 2014 First Quarter Conference Call

October 31, 2013

Consumer Healthcare Nutritionals | Rx Pharmaceuticals Active Pharmaceutical Ingredients



Important Information For Investors And Shareholders

This document does not constitute an offer to sell, or an invitation to subscribe for or purchase or purchase or exchange, any securities or the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance, exchange or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law. New Perrigo has filed with the SEC a registration statement on Form S-4 containing a joint proxy statement of Elan and Perrigo that also constitutes a prospectus of New Perrigo. The registration statement was declared effective by the SEC on October 9, 2013. Each of Perrigo and Elan has commenced mailing to its stockholders or shareholders the definitive joint proxy statement/prospectus. In addition, each of New Perrigo, Perrigo and Elan has filed and will file with the SEC other documents with respect to the proposed transaction. INVESTORS AND SECURITY HOLDERS OF PERRIGO AND ELAN ARE URGED TO READ THE DEFINITIVE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS FILED OR TO BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders may obtain free copies of the registration statement and the joint proxy statement/prospectus and other documents filed with the SEC by New Perrigo, Perrigo and Elan through the website maintained by the SEC at http://www.sec.gov. Copies of the documents filed with the SEC by New Perrigo and Perrigo are available free of charge on Perrigo's internet website at www.perrigo.com or by contacting Perrigo's Investor Relations Department at +1-269-686-1709. Copies of the documents filed with the SEC by Elan are available free of charge on Elan's internet website at www.elan.com or by contacting Elan's Investor Relations Department at +1-800-252-3526.

Perrigo, Elan and their respective directors and executive officers may be considered participants in the solicitation of proxies in connection with the transactions contemplated by the Transaction Agreement, entered into by New Perrigo, Perrigo and Elan on July 28, 2013 (the "Transaction Agreement"). Information about the directors and executive officers of Elan is set forth in its Annual Report on Form 20-F for the fiscal year ended December 31, 2012, which was filed with the SEC on February 12, 2013, its Report on Form 6-K, which was filed with the SEC on February 28, 2013, its Report on Form 6-K, which was filed with the SEC on April 25, 2013 and its Report on Form 6-K, which was filed with the SEC on August 15, 2013, its Annual Report on Form 10-K/A for the fiscal year ended June 29, 2013, which was filed with the SEC august 28, 2013, and its proxy statement for its 2012 annual meeting of stockholders, which was filed with the SEC on September 26, 2012. Other information regarding the participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, are contained in the joint proxy statement/prospectus filed with the SEC and will be contained in other relevant materials to be filed with the SEC when they become available.





This document includes certain 'forward looking statements' within the meaning of, and subject to the safe harbor created by, Section 21E of the Securities Exchange Act of 1934, as amended, with respect to the business, strategy and plans of each of Perrigo and New Perrigo, their respective expectations relating to the transactions contemplated by the Transaction Agreement and their respective future financial condition and performance, including estimated synergies. Statements that are not historical facts, including statements about Perrigo's, New Perrigo's or their respective managements' beliefs and expectations, are forward looking statements. Words such as 'believes', 'anticipates', 'estimates', 'expects', 'intends', 'aims', 'potential', 'will', 'would', 'could', 'considered', 'likely', 'estimate' and variations of these words and similar future or conditional expressions are intended to identify forward looking statements but are not the exclusive means of identifying such statements. While Perrigo and New Perrigo believe these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond Perrigo's and New Perrigo's control. By their nature, forward looking statements involve risk and uncertainty because they relate to events and depend upon future circumstances that may or may not occur. Actual results may differ materially from Perrigo's and New Perrigo's current expectations depending upon a number of factors affecting Perrigo's business, New Perrigo's business, Elan's business and risks associated with acquisition transactions. These factors include, among others: the inherent uncertainty associated with financial projections; restructuring in connection with, and successful close of, the transactions contemplated by the Transaction Agreement; subsequent integration of the transactions contemplated by the Transaction Agreement and the ability to recognize the anticipated synergies and benefits of the transactions contemplated by the Transaction Agreement; the receipt of required regulatory approvals for the transactions contemplated by the Transaction Agreement (including the approval of antitrust authorities necessary to complete the transactions contemplated by the Transaction Agreement); access to available financing (including financing for the transactions contemplated by the Transaction Agreement) on a timely basis and on reasonable terms; the risks and uncertainties normally incident to the pharmaceutical industry, including product liability claims and the availability of product liability insurance; market acceptance of and continued demand for Perrigo's, New Perrigo's and Elan's products; changes in tax laws or interpretations that could increase Perrigo's or the combined company's consolidated tax liabilities; and such other risks and uncertainties detailed in Perrigo's periodic public filings with the SEC, including but not limited to those discussed under "Risk Factors" in Perrigo's Form 10-K for the fiscal year ended June 29, 2013, in Perrigo's subsequent filings with the SEC and in other investor communications of Perrigo or New Perrigo from time to time.





The Perrigo directors accept responsibility for all the information contained in this communication. To the best of the knowledge and belief of the Perrigo directors (who have taken all reasonable care to ensure that such is the case), the information in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.

No statement in this announcement is intended to constitute a profit forecast or asset valuation for any period, nor should any statements be interpreted to mean that earnings or earnings per share will necessarily be greater or lesser than those for the relevant preceding financial periods for either Perrigo or New Perrigo, as appropriate.

Persons interested in 1% or more of any relevant securities in Perrigo or Elan may have disclosure obligations under Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules 2007 (as amended).

Barclays, which is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority in the United Kingdom, is acting exclusively for Perrigo and no one else in connection with the matters described herein and will not be responsible to anyone other than Perrigo for providing the protections afforded to its clients or for providing advice in relation to the matters described in this announcement or any transaction or any other matters referred to herein.

Unless otherwise defined, capitalized items in slides 2 – 4 of this document have the meanings given to them in the announcement dated July 29, 2013 made by Perrigo pursuant to rule 2.5 of the Irish Takeover Rules.



Combination of Perrigo and Elan Empowers Future Growth

Strengthened Financial Profile

- Increased revenue and cash flow
- Escalating royalty stream on Tysabri® - a blockbuster drug with a 19% 4-year CAGR
- \$1.9 billion in cash from Elan balance sheet

More Efficient Corporate Structure


- Irish domicile to enhance international expansion platform
- Tax rate to migrate from ~30% to high teens

Enables Growth Platform

- Superior operating company with consistent cash flows
- Ability to more successfully compete for M&A assets with global competitors
- Scale and scope to continue building differentiated business domestically and internationally
- After-tax operational synergies and tax savings >\$150 million annually
- Including synergies, accretive to adjusted EPS⁽¹⁾
 - + at least \$0.10 in FY'14
 - + \$0.70-\$0.80 in FY'15



(1) The synergy and earning enhancement statement should not be construed as a profit forecast or interpreted to mean that New Perrigo's earnings in the current or any subsequent financial period, would necessarily match or be greater than or be less than those of Perrigo and / or Elan for the relevant financial period or any other period.



(\$ in millions, except per share amounts)	Q1 2014	Q1 2013	% Change Y/Y
Net Sales	\$ 933	\$ 770	21%
Cost of Sales	577	485	19%
Gross Profit	356	285	25%
Distribution	13	11	23%
R&D	32	27	18%
SG&A	131	91	45%
Operating Income	180	157	15%
Net Income	\$ 111	\$ 106	5%
Diluted EPS	\$ 1.18	\$ 1.12	5%

Gross Margin						
Q1 2014	Q1 2013	Change				
38.2%	38.2% 37.1%					
Operating Margin*						
Оре	erating Marg	gin*				
Op e Q1 2014	erating Marg Q1 2013	g in* Change				





(\$ in millions, except per share amounts)		Q1 2014		Q1 2013	% Change Y/Y	Change as a % to sales
Net Sales	\$	933	\$	770	21%	
Adjusted Cost of Sales		554		471	17%	
Adjusted Gross Profit		380		299	27%	190 bps
Distribution		13		11	23%	
R&D		32		27	18%	
Adjusted SG&A		108		83	30%	
Adjusted Operating Income		226		177	28 %	120 bps
	•		•		000/	
Adjusted Net Income	\$	144	\$	119	20%	(10) bps
Adjusted Diluted EPS	\$	1.52	\$	1.27	20%	

Adjusted Gross Margin						
Q1 2014	Q1 2013	Change				
40.7%	40.7% 38.8%					
Adjuste	d Operating	Margin				
Adjuste Q1 2014	d Operating Q1 2013	Margin Change				



7

Quality Affordable Healthcare Products™


Perrigo

Net Sales Performance by Segment – Adjusted Financials*

(\$ in millions)	Q1 2	Q1 2014		2013	% Change Y/Y	
Consolidated Perrigo Adjusted Operating Income	\$	933 226	\$	770 177	21% 28%	
Consumer Healthcare Adjusted Operating Income		538 96		450 82	20% 18%	
Nutritionals Adjusted Operating Income		129 15		103 11	25% 35%	
Rx Pharmaceuticals Adjusted Operating Income		204 103		163 77	25% 34%	
API Adjusted Operating Income		43 23		36 14	18% 66%	








*Vitamins, Minerals, and Supplements 9 Source: IRI 52 Week Data through September 22, 2013; FDMx

Quality Affordable Healthcare Products™

Store Brand Infant Formula Market Share Growth Volume (LB) Share, including WIC

Summary - MULO						
All Powder Volume (LBS)						
Current 13 Weeks ending Sep 22, 2013						
Store Brand Market Share	% Change YoY	% Change QoQ				
12.0%	80 bps	45 bps				

Store Brand Share of <u>All</u> Powder Formulas



-Source: IRI MULO; Quarterly splits based on 12wks ending: 9/25/11, 1/15/12, 4/8/12, 7/1/12, 9/23/12, 1/13/13, 4/7/13, 6/30/13, 9/22/13 -% change may not calculate due to rounding and 13-week data in top chart vs. 12 week data in bottom graph



Consumer Healthcare Segment – Adjusted Financials*

(\$ in millions)	C	21 2014	C	21 2013	% Change Y/Y	Change as a % to sales**
Net Sales	\$	538	\$	450	20%	
Adjusted Cost of Sales		358		304	18%	
Adjusted Gross Profit		180		147	23%	90 bps
Adjusted Operating Expenses		84		65	29%	
Adjusted Operating Income	\$	96	\$	82	18%	(30) bps

			Positive Impacts	Negative Offsets
Adjus	sted Gross M	largin	Animal Health	Lower sales in contract
Q1 2014	Q1 2013	Change	Strong volumes	
33.5%	32.6%	90 bps	New products	•
Adjuste	Adjusted Operating Margin		Gross margin flow- through	 Higher DSG&A due to inclusion of Animal Health
Q1 2014	Q1 2013	Change	through	Inclusion of Animal Health
17.8%	18.1%	(30) bps		





(\$ in millions)	C	21 2014	C	1 2013	% Change Y/Y	Change as a % to sales**
Net Sales	\$	129	\$	103	25%	
Adjusted Cost of Sales		95		75	28%	
Adjusted Gross Profit		34		29	17%	(170) bps
Adjusted Operating Expenses		19		18	6%	
Adjusted Operating Income	\$	15	\$	11	35%	90 bps

26.3% 27.9% (170) bps • Higher relative costs Adjusted Operating Margin • Operating expense				Positive Impacts	Negative Offsets
Adjusted Operating Margin • Operating expense	Q1 2014	4 Q1 2013	Change		 Higher VMS and toddler food sales at lower margin Higher relative production costs
Q1 2014 Q1 2013 Change efficiencies 11.7% 10.8% 90 bps	Q1 2014	4 Q1 2013	Change	Operating expense efficiencies	





(\$ in millions)	C	1 2014	Q1 2013	% Change Y/Y	Change as a % to sales**
Net Sales	\$	204	\$ 163	25%	
Adjusted Cost of Sales		75	68	11%	
Adjusted Gross Profit		129	95	35%	480 bps
Adjusted Operating Expenses		25	18	40%	
Adjusted Operating Income	\$	103	\$ 77	34%	340 bps

			Positive Impacts	Negative Offsets
Adjus	sted Gross N	largin	Acquisitions	
Q1 2014	Q1 2013	Change	Product mix	
63.1%	58.4%	480 bps		
Adjuste	Adjusted Operating Margin		 Gross margin flow- through 	Rosemont
Q1 2014	Q1 2013	Change	unougn	Higher DSG&A in dollars and as a percentage of
50.6%	47.2%	340 bps		sales





(\$ in millions)	Q	Q1 2014		1 2013	% Change Y/Y	Change as a % to sales
Net Sales	\$	43	\$	36	18%	
Adjusted Cost of Sales		13		15	(12%)	
Adjusted Gross Profit		30		22	39%	1,040 bps
Operating Expenses		7		8	(8%)	
Adjusted Operating Income	\$	23	\$	14	66%	1,530 bps

			Positive Impacts	Negative Offsets
Adjus	sted Gross N	largin	New products	
Q1 2014	Q1 2013	Change		
70.3%	59.9%	1,040 bps		
Adjuste	d Operating	g Margin	Gross margin flow- through	
Q1 2014	Q1 2013	Change	through	
53.1%	37.8%	1,530 bps	 Lower employee-related costs 	





	FY 2014 Guidance 8/15/13 Conference Call	FY 2014 Guidance 10/31/13 Conference Call
CONSUMER HEALTHCARE Revenue Growth Y/Y Adjusted Gross Margin % Adjusted Operating Margin %	10% - 14% 33% - 37% 18% - 22%	10% - 14% 33% - 37% 18% - 22%
NUTRITIONALS Revenue Growth Y/Y Adjusted Gross Margin % Adjusted Operating Margin %	8% - 12% 26% - 30% 12% - 16%	8% - 12% 26% - 30% 12% - 16%
RX PHARMACEUTICALS Revenue Growth Y/Y Adjusted Gross Margin % Adjusted Operating Margin %	25% - 29% 58% - 62% 46% - 50%	25% - 29% 58% - 62% 46% - 50%
API Revenue Growth Y/Y Adjusted Gross Margin % Adjusted Operating Margin %	3% - 8% 52% - 56% 32% - 36%	3% - 8% 52% - 56% 32% - 36%



Perrigo FY14 Consolidated & EPS Guidance* Standalone Perrigo Guidance

	FY 2014 Guidance 8/15/13 Conference Call	FY 2014 Guidance 10/31/13 Conference Call
CONSOLIDATED PERRIGO		
Revenue Growth Y/Y	12% - 16%	12% - 16%
Adjusted Gross Margin %	38% - 42%	38% - 42%
R&D as % to Net Sales	~3.5%	~3.5%
Adjusted DSG&A as % to Net Sales	~12.5%	~12.5%
Adjusted Operating Margin %	23% - 25%	23% - 25%
Effective Tax Rate	30% - 32%	30% - 32%
Adjusted Diluted EPS	\$6.35 - \$6.60	\$6.35 - \$6.60
Y/Y Growth	13% - 18%	13% - 18%
Y/Y Growth w/out Discrete Tax [†]	15% - 19%	15% - 19%
Operating Cash Flow CAPEX	\$650M - \$700M \$150M - \$185M	\$650M - \$700M \$150M - \$185M
	†	·····

† Implied Y/Y Growth Without Discrete Tax Items Reconciliation

	FY 2013	FY 2014 Guidance
Adjusted Diluted EPS	\$5.61	\$6.35 - \$6.60
Less: Discrete Tax Items	(0.08)	-
Adjusted Diluted EPS, Excluding Discrete Tax Items	\$5.53	\$6.35 - \$6.60
Implied FY Y/Y Adjusted EPS Growth		13% - 18%
Implied FY Y/Y Adjusted EPS Growth, Excluding Discrete Ta	x Items	15% - 19%

Legend:

Y/Y = Year over Year **R&D** = Research & Development Expense **DSG&A** = Distribution, Selling, General & Administrative Expense **CAPEX** = Capital Expenditures



Corporate and Consumer Healthcare Growth – FY14 & Beyond Publicly disclosed products

Across ALL segments, we expect to launch >75 new products, resulting in >\$190M of revenue in FY 2014

Potential Rx to OTC switches

• \$10B in branded sales potential over the next 5 years











17

Consumer Healthcare FY14 Pipeline Highlights	Branded Sales (\$M)
SB version of Mucinex® Extended Release Formulas	\$160
Full year effect of Guaifenesin 600mg ER	\$135 – Launched
SB version of Children's Delsym® Liquid Suspension	\$100 – Launched
SB version of Claritin® 24HR Liqui-Gel	\$35
SB version of Advil® Congestion Relief	\$22
SB version of Vicks® Severe Cold & Flu	New

24 CAPLETS









Infant Formula SmarTub[™] Enfami Infant Upgraded National Brand style package • Improved usage experience for parents/caregivers Global Expansion **North American Formulas** Simila • Organic Toddler Dual Prebiotics • Partially Hydrolyzed & Low Lactose (Compare to Enfamil Similac Total Comfort) Gentlease Concentrates in Plastic Bottles Extensively Hydrolyzed **Chinese Formulas** Similac • Ultra-Premium Stage 1, 2 & 3

CODEX Gold Formulas

- Upgraded to include: prebiotics, lutein & DHA
- Targeting: Latin America, Africa & Middle East







Nutritionals



28 ANDAs Pending FDA approval

- ANDAs represent \$4.2B in branded sales
- 7 confirmed first-to-file ANDAs
- Additional 2 FTF ANDAs have final approval with later certain launch dates

5 Paragraph IV litigations

- Azelastine Nasal Spray (Astepro®)
- Albuterol HFA Inhaler (Proair®)
- Testosterone 1.62% Gel (Androgel®)
- Testosterone 2% Topical Solution (Axiron®)
- Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel (Epiduo®)

5 projects in clinical studies



Rx FY14 Pipeline Highlights	<u>Branded</u> Sales (\$M)	<u>Launch</u> <u>Status</u>
Generic version Prandin® Tablet	\$250	Launched
Generic version of Nitrolingual® Spray	\$65	Launched
Generic equivalent to Derma-Smoothe/FS® Oil & Lotion	~\$25	Launched
Generic equivalent to Cutivate Lotion	~\$19	Launched
Generic version of Vanos® Cream	\$93	
>3 Additional Undisclosed Products	>\$200	







Cobrek – topical foam technologies

• Expected to be \$0.04 accretive to adjusted EPS in FY13

Rosemont – oral liquid technologies

• Expected to be \$0.24 accretive to adjusted EPS in first 12-months post-February 11, 2013 close



0.12%

00 g Perrigo

.05%

Ketoconazole Foam, 2%

100 g

For Topical Use Dely. Nat For Dykthalmin, C



Foam F

betas

05

Clindamycin Phosphate Foam, 100




• Expected to be \$0.12 accretive to adjusted EPS in FY14















Appendix





Table IPERRIGO COMPANYRECONCILIATION OF NON-GAAP MEASURES

(in millions, except per share amounts)

(unaudited)

		Three Months Ended														
Consolidated			Septer	nber 28,	2013	5				Septen	nber 29,	2012			% Change	
			Non	-GAAP					Non-GAAP							As
	G	SAAP*	Adjustments*		r	As A	Adjusted*	G	GAAP*		Adjustments*		As A	Adjusted*	GAAP	Adj.
Net sales	\$	933.4	\$	-	_	\$	933.4	\$	769.8	\$	-	-	\$	769.8	21%	21%
Cost of sales		577.1		23.5	(a)		553.7		484.5		13.3	(a)		471.2	19%	17%
Gross profit		356.3		23.5	-		379.7		285.3		13.3	-		298.6	25%	27%
Operating expenses																
Distribution		13.2		-			13.2		10.8		-			10.8	23%	23%
Research and development		32.3		-			32.3		27.4		-			27.4	18%	18%
Selling and administration		129.0		20.9	(a,b,c))	108.0		90.5		7.4	(a,f)		83.2	42%	30%
Restructuring		2.1		2.1	(d)		-		-		-	_		-	-	-
Total operating expenses		176.6		23.1			153.5		128.7		7.4			121.3	37%	27%
Operating income		179.7		46.5			226.2		156.6		20.7			177.3	15%	28%
Interest, net		21.4		2.8	(e)		18.7		15.9		-			15.9	35%	18%
Other expense (income), net		1.0		-	_		1.0		(0.1)		-	_		(0.1)	-	-
Pre-tax income		157.3		49.3			206.5		140.8		20.7			161.5	12%	28%
Income tax expense		45.9		16.8	-		62.7		35.2		6.8	(g)		42.0	30%	49%
Net income	\$	111.4	\$	32.5	=	\$	143.9	\$	105.6	\$	13.9	-	\$	119.5	6%	20%
Diluted EPS	\$	1.18				\$	1.52	\$	1.12				\$	1.27	5%	20%
Diluted weighted average shares outstanding		94.7					94.7		94.3					94.3		
Effective tax rate		29.2%					30.3%		25.0%					26.0%		
Gross margin		38.2%					40.7%		37.1%					38.8%		
Operating margin		19.3%					24.2%		20.3%					23.0%		

* Amounts may not sum or cross-foot due to rounding

(a) Acquisition-related amortization

(b) Elan transaction costs of \$12.0 million

(c) Litigation settlement of \$2.5 million

(d) Restructuring charges related to Minnesota and Velcera

(e) Elan transaction costs

(f) Acquisition costs of \$1.9 million

(g) Total tax effect for non-GAAP pre-tax adjustments





Table II PERRIGO COMPANY REPORTABLE SEGMENTS RECONCILIATION OF NON-GAAP MEASURES (in millions) (unaudited)

						Three Mor	nths E	nded						
Consumer Healthcare			Septem	ber 28, 20 [.]	13				Septerr	ber 29, 20)12		% Change	
			Non-	GAAP					Non-	GAAP				As
	G	SAAP*	Adjus	tments*	As /	Adjusted*	G	SAAP*	Adjus	tments*	As	Adjusted*	GAAP	Adj.
Net sales	\$	538.5	\$	-	\$	538.5	\$	450.4	\$	-	\$	450.4	20%	20%
Cost of sales		361.5		3.4 ^(a)		358.1		304.6		1.0 ^{(a})	303.6	19%	18%
Gross profit		176.9		3.4		180.3		145.8		1.0		146.9	21%	23%
Operating expenses		87.0		2.7 ^{(a}	b)	84.3		66.5		1.2 ^{(a})	65.3	31%	29%
Operating income	\$	89.9	\$	6.1	\$	96.0	\$	79.3	\$	2.3	\$	81.6	13%	18%
Gross margin		32.9%				33.5%		32.4%				32.6%		
Operating margin		16.7%				17.8%		17.6%				18.1%		

	Three Months Ended														
Nutritionals			Septem	ber 28, 20	3				Septerr	ber 29, 2	2012			% Change	
			Non-	GAAP					Non	GAAP					As
	G	AAP*	Adjus	tments*	As	Adjusted*	GAAP* Adjustments* As Adjus		djusted*	GAAP	Adj.				
Net sales	\$	129.0	\$	-	\$	129.0	\$	103.4	\$	-	-	\$	103.4	25%	25%
Cost of sales		98.2		3.1 ^(a)		95.1		77.6		3.1	(a)		74.5	27%	28%
Gross profit		30.8		3.1		33.9		25.8		3.1	-		28.9	19%	17%
Operating expenses		23.2		4.3 ^(a)		18.8		22.0		4.3	(a)		17.7	5%	6%
Operating income	\$	7.7	\$	7.4	\$	15.1	\$	3.9	\$	7.3	-	\$	11.2	98%	35%
Gross margin		23.9%				26.3%		25.0%			_		27.9%		
Operating margin		6.0%				11.7%		3.8%					10.8%		

. .

. .

* Amounts may not sum or cross-foot due to rounding

(a) Acquisition-related amortization

(b) Restructuring charges of \$0.7 million related to Velcera

(c) Restructuring charges of \$1.4 million related to Minnesota

(d) Litigation settlement of \$2.5 million





Table II PERRIGO COMPANY REPORTABLE SEGMENTS RECONCILIATION OF NON-GAAP MEASURES (in millions) (unaudited)

							Three Mor	ths En	ded						
Rx Pharmaceuticals			Septen	nber 28,	2013			September 29, 2012							ange
			Non	-GAAP						Non-	GAAP				As
	G	AAP*	Adjus	stments*		As A	Adjusted*	G	BAAP*	Adjus	tments*	As /	Adjusted*	GAAP	Adj.
Net sales	\$	203.6	\$	-	-	\$	203.6	\$	162.9	\$	-	\$	162.9	25%	25%
Cost of sales		91.1		16.0	(a)		75.1		76.3		8.4 ^(a)		67.9	20%	11%
Gross profit		112.5		16.0	-		128.5		86.7		8.4		95.1	30%	35%
Operating expenses		29.4		4.0	(a,c,d)	25.4		18.2		-		18.2	62%	40%
Operating income	\$	83.1	\$	20.0		\$	103.1	\$	68.5	\$	8.4	\$	76.9	21%	34%
Gross margin		55.2%					63.1%		53.2%				58.4%		
Operating margin		40.8%					50.6%		42.0%				47.2%		

							Three Mon	ths End	ded						
ΑΡΙ			Septem	ber 28, 2	2013	3		September 29, 2012							ange
			Non-	GAAP						Non-	GAAP				As
	G	AAP*	Adjus	tments*		As A	Adjusted*	G	AAP*	Adjus	tments*	As A	Adjusted*	GAAP	Adj.
Net sales	\$	43.2	\$	-		\$	43.2	\$	36.4	\$	-	\$	36.4	18%	18%
Cost of sales		13.3		0.5	(a)		12.8		15.1		0.5 ^(a)		14.6	-11%	-12%
Gross profit		29.8		0.5			30.3		21.4		0.5		21.8	40%	39%
Operating expenses		7.4		-			7.4		8.0		-		8.0	-8%	-8%
Operating income	\$	22.4	\$	0.5		\$	22.9	\$	13.3	\$	0.5	\$	13.8	68%	66%
Gross margin		69.1%					70.3%		58.7%				59.9%		
Operating margin		52.0%					53.1%		36.6%				37.8%		

* Amounts may not sum or cross-foot due to rounding

(a) Acquisition-related amortization

(b) Restructuring charges of \$0.7 million related to Velcera

(c) Restructuring charges of \$1.4 million related to Minnesota

(d) Litigation settlement of \$2.5 million





Table III PERRIGO COMPANY FY 2014 GUIDANCE AND FY 2013 EPS RECONCILIATION OF NON-GAAP MEASURES (unaudited)

	Full Year Fiscal 2014 Guidance
FY14 adjusted diluted EPS range ⁽¹⁾	\$6.35 - \$6.60
Acquisition-related amortization ^(1,3)	(0.84)
FY14 GAAP equivalent range (as announced on August 15, 2013) $^{(1)}$	\$5.51 - \$5.76
Three months ended September 28, 2013 adjustments:	
Transaction charges associated with pending acquisition ⁽²⁾	(0.10)
Charge associated with litigation settlement	(0.02)
Charges associated with restructuring	(0.01)
FY14 GAAP equivalent EPS range ^(1,2)	\$5.38 - \$5.63

	Fiscal 2013
FY13 adjusted diluted EPS	\$5.61
Acquisition-related amortization ⁽³⁾	(0.668)
Charges associated with inventory step-ups	(0.077)
Charges associated with acquisition, severance and other integration-related costs	(0.061)
Charge associated with write-off of in-process R&D	(0.059)
Losses on sales of investments	(0.047)
Charge associated with restructuring	(0.018)
FY13 reported diluted EPS	\$4.68

(1) Does not include any estimate related to the Elan transaction.

(2) Only includes Elan transaction costs expensed to date as of September 28, 2013.

(3) Amortization of acquired intangible assets related to business combinations and asset acquisitions.





Table IV PERRIGO COMPANY FY 2014 GUIDANCE RECONCILIATION OF NON-GAAP MEASURES (unaudited)

	Full Year Fiscal 2014 Guidance
Consolidated	
Adjusted consolidated gross margin range ⁽¹⁾	38% - 42%
Acquisition-related amortization ^(1,3)	-2.3%
Reported consolidated gross margin range (1)	35.7% - 39.7%
Adjusted distribution, sales, general and administrative expense as % of net sales $^{(1)}$	12.5%
Acquisition-related amortization (1,3)	0.6%
Transaction charges associated with pending acquisition ⁽²⁾	0.3%
Charge associated with litigation settlement	0.1%
Charges associated with restructuring	0.1%
Reported distribution, sales, general and administrative expense as % of net sales ^(1,2)	13.6%
Adjusted consolidated operating margin range ⁽¹⁾	23% - 25%
Acquisition-related amortization (1,3)	-2.9%
Transaction charges associated with pending acquisition ⁽²⁾	-0.3%
Charge associated with litigation settlement	-0.1%
Charges associated with restructuring	-0.1%
Reported consolidated operating margin range (1,2)	19.6% - 21.6%
Consumer Healthcare	
Adjusted gross margin range	33% - 37%
Acquisition-related amortization ⁽³⁾	-0.6%
Reported gross margin range	32.4% - 36.4%
Adjusted operating margin range	18% - 22%
Acquisition-related amortization ⁽³⁾	-0.9%
Reported operating margin range	17.1% - 21.1%

(1) Does not include any estimate related to the Elan transaction.

(2) Only includes Elan transaction costs expensed to date as of September 28, 2013.

(3) Amortization of acquired intangible assets related to business combinations and asset acquisitions.





Table IV PERRIGO COMPANY FY 2014 GUIDANCE RECONCILIATION OF NON-GAAP MEASURES (unaudited)

	Full Year Fiscal 2014 Guidance
Nutritionals	
Adjusted gross margin range	26% - 30%
Acquisition-related amortization ⁽³⁾	-2.2%
Adjusted gross margin range	23.8% - 27.8%
Adjusted operating margin range	12% - 16%
Acquisition-related amortization $^{(3)}$	-5.2%
Reported operating margin range	6.8% - 10.8%
Rx Pharmaceuticals	
Adjusted gross margin range	58% - 62%
Acquisition-related amortization ⁽³⁾	-7.1%
Reported gross margin range	50.9% - 54.9%
Adjusted operating margin range	46% - 50%
Acquisition-related amortization ⁽³⁾	-7.1%
Charge associated with litigation settlement	-0.3%
Charge associated with restructuring	-0.2%
Reported operating margin range	38.4% - 42.4%
API	
Adjusted gross margin range	52% - 56%
Acquisition-related amortization $^{(3)}$	-1.1%
Reported gross margin range	50.9% - 54.9%
Adjusted operating margin range	32% - 36%
Acquisition-related amortization ⁽³⁾	-1.1%
Reported operating margin range	30.9% - 34.9%
Reported operating margin range	00.070 04.070

(1) Does not include any estimate related to the Elan transaction.

(2) Only includes Elan transaction costs expensed to date as of September 28, 2013.

(3) Amortization of acquired intangible assets related to business combinations and asset acquisitions.





Table V PERRIGO COMPANY RECONCILIATION OF NON-GAAP MEASURES (in millions) (unaudited)

	9/28/2013	
Total debt Less: Cash and cash equivalents	\$	1,983.3 (816.6)
Total net debt		1,166.7
Total shareholders' equity	-	2,469.9
Total capital	\$	3,636.6
Net debt to total capital ratio		32.1%
Consolidated	Q	1 FY12
Net sales	\$	725.3
Reported gross profit	\$	227.6
Acquisition-related amortization ⁽¹⁾		15.2
Inventory step-up	<u> </u>	27.2
Adjusted gross profit	\$	270.0
Adjusted gross margin		37.2%
Reported operating income	\$	101.5
Acquisition-related amortization ⁽¹⁾		20.0
Inventory step-up		27.2
Proceeds from sale of pipeline development projects		(3.5)
Acquisition costs		8.8
Adjusted operating income	\$	154.0
Adjusted operating margin		21.2%

(1) Amortization of acquired intangible assets related to business combinations and asset acquisitions





Table VI PERRIGO COMPANY RECONCILIATION OF NON-GAAP MEASURES (in millions) (unaudited)

	Three Months Ended			Change	
Consolidated	September 28, 2013		3 September 29, 2012		%
Net sales, as reported	\$	933.4	\$	769.8	21%
Less: FY13 acquisitions ⁽¹⁾		(64.4)		-	-
Net sales, organic	\$	869.0	\$	769.8	13%
	Three Months Ended				Change
Rx Pharmaceuticals	Septem	ber 28, 2013	Septem	ber 29, 2012	%
Net sales, as reported	\$	203.6	\$	162.9	25%
Less: Rosemont and Fera acquisitions		(22.6)		-	-
Net sales, organic	\$	181.1	\$	162.9	11%

(1) Net sales from the acquisitions of Sergeant's Pet Care Products, Inc., Rosemont Pharmaceuticals Ltd., Velcera, Inc. and Fera Pharmaceuticals LLC, which were acquired on Oct. 1, 2012, Feb. 11, 2013, April 1, 2013 and June 17, 2013, respectively.





Table VII PERRIGO COMPANY RECONCILIATION OF NON-GAAP MEASURES

(unaudited)

	Cobrek
	Fiscal 2013 Guidance
FY13 Cobrek accretion - reported diluted EPS	\$0.01
Acquisition-related amortization ⁽¹⁾	0.02
Charge associated with severance costs	0.01
FY13 Cobrek accretion - adjusted diluted EPS	\$0.04
	First 12 Months Accretion
	Post-Closing Rosemont
Rosemont accretion first 12 months post-close - reported diluted EPS	\$0.09
Acquisition-related amortization ⁽¹⁾	0.11
Charge associated with inventory step-up	0.02
Charges associated with acquisition costs	0.01
Rosemont accretion first 12 months post-close - adjusted diluted EPS	\$0.24
	Fera
	Fiscal 2014 Guidance
FY14 Fera accretion - reported diluted EPS	\$0.07
Acquisition-related amortization ⁽¹⁾	0.05
FY14 Fera accretion - adjusted diluted EPS	\$0.12

(1) Amortization of acquired intangible assets related to business combinations and asset acquisitions.

